Ventricular Arrhythmias


Arrhythmogenic Inflammatory Cardiomyopathy: A Review

Ventricular arrhythmias (VA) are commonly associated with structural heart disease and have substantial impact on patient outcomes and health system costs. Within the realm of cardiomyopathy (CM), there has been substantial progress with respect to ischaemic CM (ICM) in the understanding of infarct related scar biology and scar-mediated ventricular tachycardia (VT).

Second-degree Atrioventricular Block: Conceptions and Misconceptions

Since its first description by Hays in England in 1906, second-degree atrioventricular (AV) block has been a fascinating clinical entity, mainly due to obscure points regarding its diagnosis that emanate from misconceptions and errors regarding its proper definition.1–3 The practicing clinician should be aware of the following points that may assist a proper diagnosis and, consequently, accurate identification of patients in need of a pacemaker.

Non-invasive Cardiac Radiation for Ablation of Ventricular Tachycardia: a New Therapeutic Paradigm in Electrophysiology

Myocardial scars from infarction or replacement fibrosis in non-ischaemic cardiomyopathies are the common substrate for sustained monomorphic ventricular tachycardia (VT).1,2 In selected patients at high risk of ventricular arrhythmias, placement of an implantable cardioverter-defibrillator (ICD) is effective for prevention of sudden cardiac death.2 Although ICDs are effective in terminating VT and preventing sudden cardiac death, shocks from ICDs reduce quality of life, and multiple

Choice of Ventricular Pacing Site: the End of Non-physiological, Apical Ventricular Pacing?

The ideal pacing site in the ventricle(s) of patients with atrioventricular (AV) block has been debated for years. Despite considerable technological advances, the optimal ventricular pacing site to mimic normal human ventricular physiology and attain the best haemodynamic response remains elusive.1

Limitations and Challenges in Mapping Ventricular Tachycardia: New Technologies and Future Directions

Recurrent episodes of ventricular tachycardia (VT) in patients with structural heart disease are associated with increased mortality and morbidity, despite the life-saving benefits of implantable cardiac defibrillators (ICDs).1,2 Because ICD therapies are abortive and do not alter the underlying arrhythmogenic substrate, their reduction becomes important, especially as recurrent shocks can cause increased myocardial damage and stunning, despite the conversion of VT/VF.3,4 Antiarrhythmic drugs can reduce the number of ICD therapies, but their long-term